Previous close | 236.00 |
Open | 239.17 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 234.20 - 240.24 |
52-week range | 234.20 - 323.78 |
Volume | |
Avg. volume | 10,539 |
Market cap | 193.009B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 14.97 |
EPS (TTM) | 15.72 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 10.86 (4.60%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.